Skytap Inc
Purchase-Price Allocation
Goodwill
$11.0M
Liabilities Assumed
$29.0M
2 years of history · ending 2025-03-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2019 | FY2020 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 6.30% | 2.80% | 3.00% | 5.70% | 17.80% | 0.70% |
| Foreign Rate Differential | -18.90% | -5.90% | -8.60% | -3.90% | -17.40% | 4.50% |
| Other Adjustments | -1.60% | 0.10% | -0.20% | — | -1.40% | — |
| Nondeductible Expenses | — | — | — | -2.00% | -8.60% | 1.90% |
| Valuation Allowance Change | -59.10% | -26.10% | -16.10% | -72.00% | -67.70% | -4.10% |
| Effective Tax Rate | -62.90% | -14.00% | -21.10% | -61.60% | -102.20% | 41.90% |
Cash vs Accrual
| Item | FY2019 | FY2020 | FY2021 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $364.0M | $247.0M | $402.0M | $524.0M | $172.0M | $184.0M |
| Income Taxes Paid (Cash) | — | — | $12.0M | $167.0M | $191.0M | $149.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$11.0M
Liabilities Assumed
$29.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-12-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Workforce Rebalancing Charges | Other | +$114M | $25M | $16M |
| Charges Related To Ceasing To Use Leased And Fixed Assets | Facility Closing | +$48M | — | — |
| Charges Related To Ceasing To Use Leased Assets | Facility Closing | +$39M | — | — |
| Abandonment Of Certain Company Owned Fixed Assets | Asset Impairment / Write-Down | +$8M | — | — |
| Charges Related To Ceasing To Use Fixed Assets | Asset Impairment / Write-Down | +$8M | $5M | — |
| Charges Related To One Off Terminations | Contract Termination | +$4M | — | — |
| Workforce Rebalancing Liabilities Inherited From Former Parent | Other | +$4M | $14M | $16M |
| Charges Related To Lease Terminations | Facility Closing | −$1M | $2M | $3M |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).